Skip to main content
Premium Trial:

Request an Annual Quote

Enzo Reports 11 Percent Decline in Q2 Revenues

NEW YORK (GenomeWeb News) – Enzo Biochem reported after the close of the market on Tuesday that revenues for its fiscal second quarter dropped 11 percent year over year.

Total revenues for the three months ended Jan. 31 fell to $22.2 million from $25.0 million a year ago. By segment, clinical laboratory services shrank 6 percent to $13.3 million from $14.1 million, while product revenues slid 17 percent to $7.9 million from $9.5 million, and royalty and license fee revenues were down 23 percent to $1.0 million from $1.3 million.

Operating expenses were down by $500,000 in the quarter to $28.2 million as R&D as well as SG&A expenses were reduced. This was partially offset by increased legal expenses related to litigation against Life Technologies over a patents dispute. In November, a jury found Life Tech guilty of patent infringement and awarded Enzo $48.6 million.

Enzo's net loss for the quarter increased to $5.7 million, or $.14 per share, from a net loss of $4.2 million, or $.11 per share, a year ago.

In a statement, Enzo President Barry Weiner said that Hurricane Sandy "significantly impacted our clinical lab business" as it delayed patient visits to doctors and delayed new product approvals during the quarter, reducing revenues by an estimated $2.2 million.

"We expect clinical labs to return to the pattern of growth it had previously demonstrated during the upcoming months," he said in a statement. "In addition, we anticipate many of our newly introduced diagnostic tests should enhance results in the coming months."

Enzo finished the FY2013 second quarter with $10.0 million in cash and cash equivalents.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.